• LAST PRICE
    0.6100
  • TODAY'S CHANGE (%)
    Trending Down-0.0040 (-0.6515%)
  • Bid / Lots
    0.6050/ 52
  • Ask / Lots
    0.6267/ 5
  • Open / Previous Close
    0.6137 / 0.6140
  • Day Range
    Low 0.6000
    High 0.6324
  • 52 Week Range
    Low 0.5900
    High 10.6900
  • Volume
    10,524
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 0.614
TimeVolumeJSPR
09:32 ET3500.6137
09:37 ET1000.6137
09:39 ET1000.6137
11:00 ET2000.605001
12:28 ET21000.6163
12:30 ET2000.61
12:42 ET1000.6205
12:48 ET1000.63
12:53 ET1000.63
12:57 ET2000.63
01:02 ET1000.6175
01:09 ET1000.63
01:20 ET14500.63
01:38 ET1000.63
01:51 ET1000.6324
02:23 ET1000.63
02:27 ET1000.63
02:45 ET1000.63
03:24 ET1000.63
03:39 ET1000.63
03:48 ET1000.63
03:51 ET1000.63
03:53 ET1000.63
03:55 ET1000.63
03:57 ET3520.61
04:00 ET1000.61
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesJSPR
Jasper Therapeutics Inc
23.2M
-0.7x
---
United StatesSIOX
Sio Gene Therapies Inc
23.7M
-0.5x
---
United StatesONPH
Oncology Pharma Inc
24.7M
0.0x
---
United StatesAGRI
AgriFORCE Growing Systems Ltd
21.7M
-1.8x
---
United StatesBWV
Blue Water Vaccines Inc
20.1M
-1.2x
---
United StatesCLRB
Cellectar Biosciences Inc
17.6M
-0.4x
---
As of 2022-12-04

Company Information

Jasper Therapeutics, Inc. is a biotechnology company focused on hematopoietic cell transplant therapies. The Company has developed programs, such as JSP191, an anti-CD117 monoclonal antibody, which is in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. It is designed to enable curative allogeneic and autologous hematopoietic cell transplants and gene therapies. The Company also provides a preclinical engineered hematopoietic stem cell (eHSC) platform, which is designed to overcome limitations of allogeneic and autologous gene-edited stem cell grafts. Its programs are used to cure and expand hematopoietic stem cell therapy to cure patients with life-threatening cancers, thalassemia, sickle cell diseases, genetic diseases and autoimmune diseases. JSP191 clear hematopoietic stem cells from the bone marrow prior to transplant.

Contact Information

Headquarters
2200 Bridge Pkwy Suite #102,REDWOOD CITY, CA, United States 94065
Phone
650-549-1400
Fax
302-636-5454

Executives

Chairperson of the Board
William Lis
President, Chief Executive Officer, Director
Ronald Martell
Chief Financial Officer, Chief Operating Officer, Corporate Secretary
Jeetinder Mahal
Executive Vice President - Research and Development
Kevin Heller
Director
Judith Shizuru

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$23.2M
Revenue (TTM)
$0.00
Shares Outstanding
38.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-0.91
Book Value
$1.84
P/E Ratio
-0.7x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.